Japanese Journal of Clinical Oncology Advance Access originally published online on January 19, 2006
Japanese Journal of Clinical Oncology 2006 36(1):46-49; doi:10.1093/jjco/hyi211
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2006 Foundation for Promotion of Cancer Research
Alemtuzumab, Fludarabine and Melphalan as a Conditioning Therapy in Severe Aplastic Anemia and Hypoplastic Myelodysplastic Syndrome—Single Center Experience
Department of Clinical Oncology, BMT Unit, Central Clinical Hospital Ministry of National Defence, Warsaw, Poland
For reprints and all correspondence: Piotr Rzepecki, Department of Clinical Oncology, BMT Unit, Central Clinical Hospital Ministry of National Defence, 128 Szaserow Street, 00-909 Warsaw, Poland. E-mail: piotr_rzepecki1{at}poczta.onet.pl
Received October 5, 2005; accepted November 17, 2005
Background: Allogeneic hematopoietic stem cell transplantation is the treatment of choice in young patients with severe aplastic anemia. The main causes of failure after this procedure are graft versus host disease, infections and graft failure, often exacerbated by large numbers of transfusions and prolonged disease duration before transplant.
Methods: We report the results of allografting following conditioning with fludarabine, alemtuzumab and melphalan in: five patients with severe aplastic anemia and one with hypoplastic myelodysplastic syndrome. All patients had matched sibling donors. Source of hematopoietic stem cell was: bone marrow—2, blood—3, bone marrow and blood—1. The age of recipients was 18–26 years. Four patients received their graft as the first line therapy and two after failure of cyclosporine and antithymocyte globulin treatment. Number of transfused units including red blood cells and platelets before transplantation was 8–100 (median: 22) and 10–32 (median: 11), respectively. All donors and recipients were CMV-seropositive. Conditioning consisted of: alemtuzumab 30 mg/d (day –7 to –5), fludarabine 30 mg/m2 (days –7 to –3) and melphalan 140 mg/m2 at the day –2.
Results: The time to granulocytes and platelets recovery was 15 and 25 days, respectively. All patients achieved full donor chimerism on day +60. Only two patients needed ganciclovir as preemptive therapy. Recurrent parvovirus B19 infection with pure red cell aplasia and acute viral B hepatitis was observed in one case. Pure red cell aplasia was successfully treated with immunoglobulins and cyclosporine discontinuation. With a follow-up of 16–39 (median: 29) months all patients are alive, and neither graft failure nor graft versus host disease, or any no other severe complications, was observed.
Conclusions: Our study suggests that transplantation of hematopoietic stem cell using alemtuzumab, fludarabine and melphalan as a conditioning therapy is safe, inexpensive and effective treatment for patients with severe aplastic anemia, including multi-transfused adults having their disease for a long time.
Key Words: aplastic anemia • hypoplastic myelodysplastic syndrome • alemtuzumab • fludarabine